Shanghai Pharmaceuticals: Pregabalin capsules received drug registration certificate in the Philippines.

Shanghai Pharmaceuticals announced that the pregabalin capsules produced by its subsidiary Changzhou Pharmaceutical Factory have received a drug registration certificate issued by the Food and Drug Administration of the Philippines and have been approved for listing. The drug comes in three specifications: 50mg, 75mg, and 150mg, mainly used for the treatment of neuralgia and as an adjunctive treatment for epilepsy. As of the announcement date, the company has invested a certain amount of research and development expenses for the listing of this drug in the Southeast Asian market. The total sales of the same specification drug already on the market in the Philippines in 2024 is 13.37 million US dollars. This approval will have a positive impact on the company's expansion into overseas markets, but due to various uncertain factors, drug sales may not meet expectations.